Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


Liang Xu

Liang Xu

University of Kansas Cancer Center


After obtained his M.D. and Ph.D. in Gastroenterology at the Fourth Military Medical University of China in 1992, he did post-doc research on molecular biology at University of Louvain, Belgium, 1994, then at Stanford University, 1996. He moved to the Georgetown University and developed a novel non-viral tumor-targeted delivery system for cancer therapy, which is in Phase II clinical trials. In 2002, he joined the faculty at University of Michigan to discover the novel small molecule inhibitors of anti-apoptotic proteins. He is a co-inventor of the first Bcl-2 inhibitor that entered into clinical trials. In 2010, he obtained a Rising Star Award and became an Associate Professor with Tenure at University of Kansas Cancer Center. He has >25 patents with four INDs in advanced clinical trials. He is now a Professor of Cancer Biology at University of Kansas and has been funded by NIH, DOD and Komen Foundation. He is now working on cancer drug discovery and immunotherapy targeting cancer stem cells.

Research Interest

Cancer; Cancer Immunology and Immunotherapy; Cancer Stem cells; Cancer Antibodies